Business
Endonovo Therapeutics Provides Update on Pre-Clinical Studies
Endonovo Therapeutics Provides Update on Pre-Clinical Studies.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Provides Update on Pre-Clinical Studies\n \n \nEndonovo Therapeutics Provides Update on Pre-Clinical Studies\n\nCompany Provides Interim Results on Treatment and Prevention of Heart Failure following Myocardial Infarction using Non-Invasive Electroceutical\n\n \n LOS ANGELES, CA--(Marketwired - Sep 26, 2017) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today provided an update on its pre-clinical studies and interim results from its pre-clinical study to assess the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction.\n Interim results from the Company's ongoing pre-clinical study to assess the effectiveness of its Immunotronics™ platform in the treatment and prevention of heart failure following myocardial infarction have demonstrated improved cardiac function and less ventricular remodeling, as evaluated using echocardiography in infarcted animals treated with the Company's non-invasive electroceutical two or three times per day for four weeks when compared to the control group. The Company expects to provide final results including histology and cytokine data in the next few weeks.\n \"We are very excited about these interim results,\" stated Endonovo CEO, Alan Collier. \"We not only want to demonstrate the effectiveness of our non-invasive electroceutical, but we also want to create an easy to use device that can reduce the treatment time required to produce a meaningful effect. Our belief is that the future of medicine is electric and that our non-implantable and non-invasive electroceutical platform will be at the forefront of bioelectronic medicine,\" said Mr. Collier.\n The Company is currently preparing to conduct additional pre-clinical studies using its newly developed electroceutical technology in the treatment of critical limb ischemia, kidney disease and Non-Alcoholic Steatohepatitis (NASH).\n \"We remain committed to keeping our shareholders up to date with the status of our ongoing research and development efforts and we appreciate the patience of our shareholders as we continue down this path together,\" concluded Mr. Collier. \n About Endonovo Ther...